Proactive Investors - Run By Investors For Investors

OptiBiotix Health signs licence deal to sell cholesterol management supplements in Vietnam

Three-year deal guarantees market exclusivity for local partner if it hits minimum sales targets
With a rapidly-ageing population, around 20% of the Vietnamese population suffers from high blood pressure

OptiBiotix Health PLC (LON:OPTI) has struck a deal with a local distributor to market its ProBiotix arm’s cholesterol management products in Vietnam.

ProBiotix has signed a three-year licence deal with Singapore-based Biovagen Healthcare for its Vietnam subsidiary Viet Phap to exclusively market the CholBiome and CholBiome x3 products in the south-east Asian country.

READ: OptiBiotix Health - the commercial momentum continues to build

Biovagen, which will cover the costs of registering the products with local health authorities, is only guaranteed market exclusivity if it hits minimum sales orders.

OptiBiotix said Biovagen will need to secure half the minimum quantity for the first year within six months of signing the agreement to maximise the financial return for both sides.

The AIM-listed group, which has been mulling a potential spin-off float of the ProBiotix business, said Vietnam was a key market, with a fast growing population and economy, including a rapidly-ageing population where cardiovascular disease is responsible for 31% of all deaths and around 20% of the population suffers from high blood pressure.

OptiBiotix said the Biovagen agreement was “a strategic step” to take the CholBiome products to international markets under its own OptiBiotix brand label or white label distributors brand products.

WATCH: OptiBiotix appoints US-based chief executive for ProBiotix Health

“As manufacturing volumes increase the unit costs of each product decreases improving OptiBiotix's margins. This strategy also creates a global demand for OptiBiotix's cholesterol LPLDL probiotic within CholBiome products which helps build brand recognition and brand value.”

Viet Phap, which currently represents some of the main global generic drugs, specialty pharmaceuticals and probiotics companies, will market CholBiome, which includes probiotic strain Lactobacillus plantarum (LPLDL), as BioStatin, and cholesterol reduction supplement CholBiome x3 as BioStatin Platinum.

OptiBiotix business development director Luis Gosálbez said the requirement for annual and increasing guaranteed minimum sales orders “helps builds recurring revenues and extends the sale of LPLDL into another territory to support further sales growth”.

Shares in OptiBiotix were up 2% to 84p in early trading on Monday.


View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

cancer cell
The San Diego-based company has developed a patented liquid biopsy technology called Target Selector the detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA)
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
healthy gut
Here we take a look at AIM-listed life sciences group, OptiBiotix Health

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use